Ivosidenib
Ivosidenib Phase 1 (glioma)
Servier · Phase 1 · Completed · Enrollment 174
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Ivosidenib, non-enhancing glioma | recurrent non-enhancing IDH1-mutant glioma | Phase 1 doses | Single arm | n/r | median PFS: 13.6 months, 95% CI 9.2 to 33.2 |